Biopharmaceutical company Halozyme Therapeutics (NASDAQ:HALO) exceeded market revenue expectations in Q3 CY2025, with sales up 22.1% year on year to $354.3 million. Full-year revenue guidance of $1.34 billion at the midpoint surpassed analyst estimates by 1.5%. Non-GAAP profit of $1.72 per share was 5.5% above consensus estimates. The company’s adjusted EBITDA for the full year is $910 million at the midpoint, beating analyst estimates by 30.1%. Halozyme Therapeutics develops and licenses its proprietary ENHANZE technology. Revenue growth has been strong with a 44.2% compounded annual growth rate over the last five years. Adjusted operating margin was 61.5%, down from the same quarter last year. Adjusted EPS was $1.72, a 5.5% beat on analyst estimates. Investors showed some disappointment, with shares trading down 1.6% to $66.25 following the results.

Read more at StockStory Communications: Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025